Molecular biomarkers in advanced renal cell carcinoma

Clinical Cancer Research

Volumn 20, Issue 8, 2014, Pages 2060-2071

  Maroto, Pablo ^a   Rini, Brian ^b  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^b TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANGIOGENIC FACTOR; CARBONATE DEHYDRATASE IX; EVEROLIMUS; LACTATE DEHYDROGENASE; MAMMALIAN TARGET OF RAPAMYCIN; MYC PROTEIN; PAZOPANIB; PLACEBO; PROTEIN KINASE B; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TUMOR MARKER; VASCULOTROPIN A; VASCULOTROPIN C; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3; VON HIPPEL LINDAU PROTEIN; VASCULOTROPIN RECEPTOR;

ADVANCED CANCER; ARTICLE; DRUG EFFICACY; ENDOTHELIAL PROGENITOR CELL; HUMAN; KIDNEY CARCINOMA; MUTATIONAL ANALYSIS; NONHUMAN; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; VALIDATION PROCESS; VHL GENE; CARCINOMA, RENAL CELL; GENETICS; KAPLAN MEIER METHOD; KIDNEY NEOPLASMS; METABOLISM; MOLECULARLY TARGETED THERAPY; PROCEDURES;

CARCINOMA, RENAL CELL; HUMANS; KAPLAN-MEIER ESTIMATE; KIDNEY NEOPLASMS; MOLECULAR TARGETED THERAPY; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84898958636     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-1351     Document Type: Article

References (79)

1. Escudier B, Eisen T, StadlerWM,Szczylik C, Oudard S, Siebels M, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125-34.
2. Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007;370:2103-11.
3. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356:2271-81.
4. Rini BI, Michaelson MD, Rosenberg JE, Bukowski RM, Sosman JA, StadlerWM,et al. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol 2008;26:3743-8.
5. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27:3584-90.
6. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 2010;116: 4256-65.
7. Rini BI, Escudier B, Tomczak P, Karin A, Szczylik C, Hutson TE, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 2011;378:1931-9.
8. Gore ME, Larkin JMG. Challenges and opportunities for converting renal cell carcinoma into a chronic disease with targeted therapies. Br J Cancer 2011;104:399-406.
9. Dancey JE, Dobbin KK, Groshen S, Jessup JM, Hruszkewycz AH, Koehler M, et al. Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents. Clin Cancer Res 2010;16:1745-55.
10. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Staehler M, et al. Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 2009;27:3312-8.
11. Harmon CS, Figlin RA, Hutson TE, Michaelson MD, Negrier S, Kim ST, et al. Circulating protein biomarkers of sunitinib and interferon-A efficacy in treatment-naive patients with metastatic renal cell carcinoma. J Clin Oncol 29:2011 (suppl; abstr 10525).
12. DePrimo SE, Bello CL, Smeraglia J, Baum CM, Spinella D, Rini BI, et al. Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins. J Transl Med 2007;5:32.
13. Gruenwald V, Beutel G, Schuch-Jantsch S, Reuter C, Ivanyi P, Ganser A, et al. Circulating endothelial cells are an early predictor in renal cell carcinoma for tumor response to sunitinib. BMC Cancer 2010;10:695.
14. Kontovinis LF, Papazisis KT, Touplikioti P, Andreadis C, Mouratidou D, Kortsaris AH. Sunitinib treatment for patientswith clear-cell metastatic renal cell carcinoma: clinical outcomes and plasma angiogenesis markers. BMC Cancer 2009;9:82.
15. Liu G, Tran HT, Lin Y, Martin A, Zurita AJ, Sternberg CN, et al. Plasma cytokine and angiogenic factors (CAFs) predictive of clinical benefit and prognosis in patients (pts) with advanced or metastatic renal cell cancer (mRCC) treated in phase III trials of pazopanib (PAZO). J Clin Oncol 29: 2011 (suppl 7; abstr 334).
16. Armstrong AJ, George DJ, Halabi S. Serum lactate dehydrogenase predicts for overall survival benefit in patients with metastatic renal cell carcinoma treated with inhibition of mammalian target of rapamycin. J Clin Oncol 2012;30:3402-7.
17. Choueiri TK, Vaziri SA, Jaeger E, Elson P, Wood L, Bhalla IP, et al. von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma. J Urol 2008;180:860-6.
18. Gordan JD, Lal P, Dondeti VR, Letrero R, Parekh KN, Oquendo CE, et al. HIF-A effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. Cancer Cell 2008;14: 435-46.
19. Maroto P, Esteban E, Fernandez-Parra E, Mendez-Vidal MJ, Domenech M, Leon L, et al. C-myc as a new predictive biomarker for sunitinib in metastatic renal clear cell carcinoma. Ann Oncol 23:2012 (suppl 9; abstr 832P).
20. Cho D, Signoretti S, Dabora S, Regan M, Seeley A, Mariotti M, et al. Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma. Clin Genitourin Cancer 2007;5:379-85.
21. Jonasch E, Corn P, Pagliaro LC, Warneke CL, JohnsonMM,Tamboli P, et al. Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma: clinical and biomarker analysis. Cancer 2010;116:57-65.
22. van der Veldt AA, Eechoute K, Gelderblom H, Gietema J, Guchelaar HJ, van Erp NP, et al. Genetic polymorphisms associated with a prolonged progression-free survival in patients with metastatic renal cell cancer treated with sunitinib. Clin Cancer Res 2011;17:620-9.
23. Farfan CA, Sepulveda J, Benitez J, de Velasco G, Villacampa F, de la Rosa F, et al. Prospective exploratory analysis of the association between genetic polymorphisms and sunitinib toxicity and efficacy in metastatic renal-cell carcinoma. J Clin Oncol 30:2012 (suppl; abstr 4620).
24. Xu CF, Bing NX, Ball HA, Rajagopalan D, Sternberg CN, Hutson TE, et al. Pazopanib efficacy in renal cell carcinoma: evidence for predictive genetic markers in angiogenesis-related and exposure-related genes. J Clin Oncol 2011;29:2557-64.
25. Garcia-Donas J, Esteban E, Leandro-Garcia LJ, Castellano DE, Del Alba AG, Climent MA, et al. Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renalcell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study. Lancet Oncol 2011;12:1143-50.
26. van Erp NP, Eechoute K, van der Veldt AA, Haanen JB, Reyners AK, Mathijssen RH, et al. Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity. J Clin Oncol 2009;27: 4406-12.
27. van Erp NP, Mathijssen RH, van der Veldt AA, Haanen JB, Reyners AK, Eechoute K, et al. Myelosuppression by sunitinib is flt-3 genotype dependent. Br J Cancer 2010;103:757-8.
28. Kim JJ, Vaziri SA, Rini BI, Elson P, Garcia JA, Wirka R, et al. Association of VEGF and VEGFR2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal cell carcinoma patients treated with sunitinib. Cancer 2012;118:1946-54.
29. Tugues S, Koch S, Gualandi L, Li X, Claesson-Welsh L. Vascular endothelial growth factors and receptors: anti-angiogenic therapy in the treatment of cancer. Mol Aspects Med 2011;32:88-111.
30. Jacobsen J, Grankvist K, Rasmuson T, Bergh A, Landberg G, Ljungberg B. Expression of vascular endothelial growth factor protein in human renal cell carcinoma. BJU Int 2004;93:297-302.
31. Klatte T, Seligson DB, Riggs SB, Leppert JT, Berkman MK, Kleid MD, et al. Hypoxia-inducible factor 1 alpha in clear cell renal cell carcinoma. Clin Cancer Res 2007;13:7388-93.
32. Pena C, Lathia C, Shan M, Escudier B, Bukowski RM. Biomarkers predicting outcome in patients with advanced renal cell carcinoma: Results from sorafenib phase III Treatment Approaches in Renal Cancer Global Evaluation Trial. Clin Cancer Res 2010;16:4853-63.
33. Ebos JM, Lee CR, Christensen JG, Mutsaers AJ, Kerbel RS. Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy. Proc Natl Acad Sci U S A 2007;104:17069-74.
34. Lindauer A, Di Gion P, Kanefendt F, Tomalik-Scharte D, Kinzig M, Rodamer M, et al. Pharmacokinectic/pharmacodynamic modeling of biomarker response to sunitinib in healthy volunteers. Clin Pharmacol Ther 2010;87:601-8.
35. Gordon MS, Margolin K, Talpaz M, Sledge GW Jr, Holmgren E, Benjamin R, et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 2001;19:843-50.
36. Loupakis F, Falcone A, Masi G, Fioravanti A, Kerbel RS, Del Tacca M, et al. Vascular endothelial growth factor levels in immunodepleted plasma of cancer patients as a possible pharmacodynamic marker for bevacizumab activity. J Clin Oncol 2007;25:1816-8.
37. Breen EC, Reynolds SM, Cox C, Jacobson LP, Magpantay L, Mulder CB, et al. Multisite comparison of high-sensitivity multiplex cytokine assays. Clin Vaccine Immunol 2011;18:1229-42.
38. Zurita AJ, Jonasch E, Wang X, Khajavi M, Yan S, Du DZ, et al. A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma. Ann Oncol 2012;23:46-52.
39. Tran HT, Liu Y, Zurita AJ, Lin Y, Baker-Neblett KL, Martin AM, et al. Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials. Lancet Oncol 2012;13:827-37.
40. Liu Y, Tran HT, Lin Y, Martin A, Zurita AJ, Sternberg CN, et al. Circulating baseline plasma cytokines and angiogenic factors (CAF) as markers of tumor burden and therapeutic response in a phase III study of pazopanib for metastatic renal cell carcinoma (mRCC). J Clin Oncol 29:2011 (suppl; abstr 4553).
41. Zurita-Saavedra A, Liu Y, Lin Y, Tran HT, Pandite LN, Heymach JV. Multivariate analysis of cytokines and angiogenic factors (CAFs) and established prognostic parameters in metastatic renal cell carcinoma (mRCC) patients receiving pazopanib or placebo. Ann Oncol 23:2012 (suppl 9; abstr 791PD).
42. Bertolini F, Shaked Y, Mancuso P, Kerbel RS. The multifaceted circulating endothelial cell in cancer: towards marker and target identification. Nat Rev Cancer 2006;6:835-45.
43. Bhatt RS, Zurita AJ, O'Neill A, Norden-Zfoni A, Zhang L, Wu HK, et al. Increased mobilisation of circulating endothelial progenitors in von Hippel-Lindau disease and renal cell carcinoma. Br J Cancer 2011; 105:112-7.
44. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002;20:289-96.
45. Ward CS, Venkatesh HS, Chaumeil MM, Brandes AH, Vancriekinge M, Dafni H, et al. Noninvasive detection of target modulation following phosphatidylinositol 3-kinase inhibition using hyperpolarized 13C magnetic resonance spectroscopy. Cancer Res 2010;70: 1296-305.
46. Patil S, Figlin RA, Hutson TE, Michaelson MD, Negrier S, Kim ST, et al. Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma. Ann Oncol 2011;22:295-300.
47. Terakawa T, Miyake H, Kusuda Y, Fujisawa M. Expression level of vascular endothelial growth factor receptor-2 in radical nephrectomy specimens as a prognostic predictor in patients with metastatic renal cell carcinoma treated with sunitinib. Urol Oncol 2013;31:493-8.
48. Paule B, Bastien L, Deslandes E, Cussenot O, Podgorniak MP, Allory Y, et al. Soluble isoforms of vascular endothelial growth factor are predictors of response to sunitinib in metastatic renal cell carcinomas. PLoS ONE 2010;5:e10715.
49. Cowey CL, Rathmell WK. VHL gene mutations in renal cell carcinoma: role as a biomarker of disease outcome and drug efficacy. Curr Oncol Rep 2009;11:94-101.
50. Brauch H, Weirich G, Brieger J, Glavac D, Rodl H, Eichinger M, et al. VHL alterations in human clear cell renal cell carcinoma: association with advanced tumor stage and a novel hot spot mutation. Cancer Res 2000;60:1942-8.
51. Kondo K, Yao M, Yoshida M, Kishida T, Shuin T, Miura T, et al. Comprehensive mutational analysis of the VHL gene in sporadic renal cell carcinoma: relationship to clinicopathological parameters. Genes Chromosomes Cancer 2002;34:58-68.
52. Gimenez-Bachs JM, Salinas-Sanchez AS, Sanchez-Sanchez F, Lorenzo- Romero JG, Donate-Moreno MJ, Pastor-Navarro H, et al. Determination of VHL gene mutations in sporadic renal cell carcinoma. Eur Urol 2006;49:1051-7.
53. Smits KM, Schouten LJ, van Dijk BA, Hulsbergen-van de Kaa CA, Wouters KA, Oosterwijk E, et al. Genetic and epigenetic alterations in the von Hippel-Lindau gene: the influence on renal cancer prognosis. Clin Cancer Res 2008;14:782-7.
54. Hutson TE, Davis ID, Machiels JP, De Souza P, Baker KL, Bordogna W, et al. Biomarker analysis and final efficacy and safety results of a phase II renal cell carcinoma trial with pazopanib (GW786034), a multi-kinase angiogenesis inhibitor. J Clin Oncol 26:2008 (suppl; abstr 5046).
55. Pawl-owski R,Muhl SM, Sulser T, Krek W, Moch H, Schraml P. Loss of PBRM1 expression is associated with renal cell carcinoma progression. Int J Cancer 2013;132:E11-7.
56. Pe~na-Llopis S, Vega-Rubín-de-Celis S, Liao A, Leng N, Pavía-Jimenez A, Wang S, et al. BAP1 loss defines a new class of renal cell carcinoma. Nat Genet 2012;44:751-9.
57. Sato Y, Yoshizato T, Shiraishi Y, Maekawa S, Okuno Y, Kamura T, et al. Integrated molecular analysis of clear-cell renal cell carcinoma. Nat Genet 2013;45:860-7.
58. The Cancer Genome Atlas (TCGA) Data Portal. Kidney renal clear cell carcinoma. [Cited 2013, September 5]. Available from: https://tcgadata. nci.nih.gov/tcga/.
59. Kapur P, Pena-Llopis S, Christie A, Zhrebker L, Pavía-Jimenez A, Rathmell WK, et al. Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation. Lancet Oncol 2013;14: 159-67.
60. Choueiri TK, ReganMM,Rosenberg JE,OhWK, Clement J, AmatoAM, et al. Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy. BJU Int 2010;106:772-8.
61. Choueiri TK, Cheng S, Qu AQ, Pastorek J, Atkins MB, Signoretti S. Carbonic anhydrase IX as a potential biomarker of efficacy in metastatic clear-cell renal cell carcinoma patients receiving sorafenib or placebo: Analysis from the treatment approaches in renal cancer global evaluation trial (TARGET). Urol Oncol 2013;31: 1788-93.
62. Di Nicolantonio F, Arena S, Tabernero J, Grosso S, Molinari F, Macarulla T, et al. Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. J Clin Invest 2010;120:2858-66.
63. Houk BE, Bello CL, Poland B, Rosen LS, Demetri GD, Motzer RJ. Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis. Cancer Chemother Pharmacol 2010;66:357-71.
64. Xu CF, Johnson T, Choueiri TK, Deen KC, Xue Z, Spraggs CF, et al. Association of IL8 polymorphisms with overall survival in patients with renal cell carcinoma in COMPARZ (pazopanib versus sunitinib phase III study). J Clin Oncol 31:2013 (suppl; abstr 4519).
65. Schneider BP, Wang M, Radovich M, Sledge GW, Badve S, Thor A, et al. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 2008;26:4672-8.
66. Xu CF, Reck BH, Goodman VL, Xue Z, Huang L, Barnes MR, et al. Association of the hemochromatosis gene with pazopanib-induced transaminase elevation in renal cell carcinoma. J Hepatol 2011;54: 1237-43.
67. Xu CF, Reck BH, Xue Z, Huang L, Baker KL, Chen M, et al. Pazopanibinduced hyperbilirubinemia is associated with Gilbert's syndrome UGT1A1 polymorphism. Br J Cancer 2010;102:1371-7.
68. Mandrekar SJ, Sargent DJ. Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges. J Clin Oncol 2009;27:4027-34.
69. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM, on behalf of the Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics. Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 2005;97: 1180-4.
70. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001; 27:383-91.
71. Stewart GD, O'Mahony FC, Powles T, Riddick AC, Harrison DJ, Faratian D. What can molecular pathology contribute to the management of renal cell carcinoma? Nat Rev Urol 2011;8: 255-65.
72. Holland NT, Pfleger L, Berger E, Ho A, Bastaki M. Molecular epidemiology biomarkers-sample collection and processing considerations. Toxicol Appl Pharmacol 2005;206:261-8.
73. Gerlinger M, Rowan AJ, Horswell S, Math M, Larkin J, Endesfelder D, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012;366:883-92.
74. Thompson RH, Dong H, Lohse CM, Leibovich BC, Blute ML, Cheville JC, et al. PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. Clin Cancer Res 2007;13:1757-61.
75. Thompson RH, Kuntz SM, Leibovich BC, Dong H, Lohse CM, Webster WS, et al. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res 2006;66: 3381-5.
76. Wulfken LM, Moritz R, Ohlmann C, Holdenrieder S, Jung V, Becker F, et al. MicroRNAs in renal cell carcinoma: diagnostic implications of serum miR-1233 levels. PLoS ONE 2011;6:e25787.
77. Bluemke K, Bilkenroth U, Meye A, Fuessel S, Lautenschlaeger C, Goebel S, et al. Detection of circulating tumor cells in peripheral blood of patients with renal cell carcinoma correlates with prognosis. Cancer Epidemiol Biomarkers Prev 2009;18:2190-4.
78. Swanton C, Larkin JM, Gerlinger M, Eklund AC, Howell M, Stamp G, et al. Predictive biomarker discovery through the parallel integration of clinical trial and functional genomics datasets. Genome Med 2010;2:53.
79. Eisen T, Sternberg CN, Robert C, Mulders P, Pyle L, Zbinden S, et al. Targeted therapies for renal cell carcinoma: review of adverse event management strategies. J Natl Cancer Inst 2012:104:93-113.